Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration

被引:32
作者
Saidinejad, M [1 ]
Ewald, MB [1 ]
Shannon, MW [1 ]
机构
[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Massachusetts & Rhode Isl Poison Control Ctr,Prog, Boston, MA 02115 USA
关键词
trimethoprim-sulfamethoxazole; altered metal status; hallucinations; immune competent; toxicity; adverse reaction; central nervous system;
D O I
10.1542/peds.2004-1352
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
We describe a rare adverse reaction to trimethoprim-sulfamethoxazole (TMP-SMX; Septra, Bactrim) in an immune-competent female adolescent. She was prescribed TMP-SMX for a urinary tract infection, which she had developed while being treated in the hospital for an extensive leg cellulitis. Shortly after receiving her third dose of TMP-SMX, she developed an acute altered mental status with agitation as well as vivid visual and auditory hallucinations. After prompt discontinuation of TMP-SMX, the patient slowly began to improve and was able to return to her baseline mental status within 10 days. No residual mental status changes were present. Despite the recent emergence of multidrug-resistant bacterial pathogens, TMP-SMX, one of the first-generation broad-spectrum antibiotics, continues to be widely prescribed, in part because of its low cost and its easy availability. It is generally well tolerated and is associated with relatively few adverse effects. More common toxicities associated with TMP-SMX include hypersensitivity reactions, bone marrow suppression, and gastrointestinal side effects. Central nervous system toxicity is very rare; when reported, it has been in an immune-compromised or an elderly patient.
引用
收藏
页码:E739 / E741
页数:3
相关论文
共 15 条
  • [1] Brett AS, 1999, AM J GASTROENTEROL, V94, P267
  • [2] TRIMETHOPRIM A SULPHONAMIDE POTENTIATOR
    BUSHBY, SRM
    HITCHING.GH
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1968, 33 (01) : 72 - +
  • [3] CENTRAL-NERVOUS-SYSTEM WHIPPLES-DISEASE - RELAPSE DURING THERAPY WITH TRIMETHOPRIM-SULFAMETHOXAZOLE AND REMISSION WITH CEFIXIME
    COOPER, GS
    BLADES, EW
    REMLER, BF
    SALATA, RA
    BENNERT, KW
    JACOBS, GH
    [J]. GASTROENTEROLOGY, 1994, 106 (03) : 782 - 786
  • [4] HOFSTEDE HJ, 1999, BR J CLIN PHARM MAY, V47, P571
  • [5] Huovinen P, 2001, CLIN INFECT DIS, V32, P1608, DOI 10.1086/320532
  • [6] PHARMACOKINETIC STUDIES OF CO-TRIMOXAZOLE IN MAN AFTER SINGLE AND REPEATED DOSES
    KREMERS, P
    DUVIVIER, J
    HEUSGHEM, C
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1974, 14 (2-3) : 112 - 117
  • [7] Trimethoprim-sulfamethoxazole revisited
    Masters, PA
    O'Bryan, TA
    Zurlo, J
    Miller, DQ
    Joshi, N
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (04) : 402 - 410
  • [8] Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole
    Mori, H
    Kuroda, Y
    Imamura, S
    Toyoda, A
    Yoshida, I
    Kawakami, M
    Tabei, K
    [J]. INTERNAL MEDICINE, 2003, 42 (08) : 665 - 669
  • [9] Patey O, 1998, SCAND J INFECT DIS, V30, P530, DOI 10.1080/00365549850161610
  • [10] Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patient
    Patterson, RG
    Couchenour, RL
    [J]. PHARMACOTHERAPY, 1999, 19 (12): : 1456 - 1458